title: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
abstract: OBJECTIVE
  The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD).
  
  
  METHODS
  In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly assigned to receive 6 weeks of treatment with either atomoxetine (administered once daily) or placebo.
  
  
  RESULTS
  Outcomes among atomoxetine-treated patients were superior to those of the placebo treatment group as assessed by investigator, parent, and teacher ratings. The treatment effect size (0.71) was similar to those observed in previous atomoxetine studies that used twice-daily dosing. Parent diary ratings suggested that drug-specific effects were sustained late in the day. Discontinuations due to adverse events were low (less than 3%) for both treatment groups, and no serious safety concerns were observed.
  
  
  CONCLUSIONS
  Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.
authors.affiliation: Lilly Research Laboratories, Indianapolis, IN 46285, USA. dmichelson@lilly.com
authors.forename: David
authors.initials: D
authors.lastname: Michelson
authors.forename: Albert J
authors.initials: AJ
authors.lastname: Allen
authors.forename: Joan
authors.initials: J
authors.lastname: Busner
authors.forename: Charles
authors.initials: C
authors.lastname: Casat
authors.forename: David
authors.initials: D
authors.lastname: Dunn
authors.forename: Christopher
authors.initials: C
authors.lastname: Kratochvil
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Newcorn
authors.forename: F Randy
authors.initials: FR
authors.lastname: Sallee
authors.forename: R Bart
authors.initials: RB
authors.lastname: Sangal
authors.forename: Keith
authors.initials: K
authors.lastname: Saylor
authors.forename: Scott
authors.initials: S
authors.lastname: West
authors.forename: Douglas
authors.initials: D
authors.lastname: Kelsey
authors.forename: Joachim
authors.initials: J
authors.lastname: Wernicke
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Trapp
authors.forename: Donald
authors.initials: D
authors.lastname: Harder
mesh_terms: D000293:Adolescent; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D010552:Personality Assessment; D011437:Propylamines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride